Document:

<PAGE>   1
                                                                   EXHIBIT 10.10

THE SYMBOL "[*]" IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

UNIVERSITY OF CALIFORNIA, BERKELEY
OFFICE OF TECHNOLOGY LICENSING                                [UC BERKELEY LOGO]

===============================================================================

                               LICENSE AGREEMENT

                                                       Case No. B 90-001

===============================================================================

Effective 1/16/91, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California
Corporation, whose legal address is 300 Lakeside Drive, Oakland, California
94612-3550, acting through its Office of Technology Licensing, at the
University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley CA
94704-1318, ("REGENTS"), and Molecular Dynamics, having a principal place of
business at 880 East Arques Avenue, Sunnyvale, CA 94086, ("LICENSEE"), agree as
follows:

1.  BACKGROUND

     1.1. REGENTS have an assignment to the Laser Excited Confocal Fluorescence
          Gel Scanner ("Invention[s]"), as described in Case B90-001 and any
          Licensed Patent(s), as hereinafter defined, which may issue to such
          Invention(s).

     1.2. REGENTS wish to have said Invention(s) perfected and marketed at the
          earliest possible time in order that products resulting therefrom may
          be available for public use and benefit.

     1.3. LICENSEE wishes to acquire a license under said Licensed Patent(s),
          for the purpose of undertaking development, to manufacture, use, and
          sell Licensed Product(s) in the Field-of-Use of biological
          instrumentation.

     1.4. The Invention(s) were made in the course of research supported by the
          Department of Energy under Contract/Grant number DE-FG03-88ER60706 and
          National Science Foundation Contract/Grant number BBS-8720382.

2.  DEFINITIONS

     2.1  "Licensed Patent(s)" means any Letters Patent issued upon REGENTS'
          U.S. Patent Application, Serial Number 463,757, filed 12 January 1990,
          including the information contained in such application with respect
          to the Invention(s), any foreign patents corresponding thereto, and/or
          any divisions, continuations, or reissue thereof, and continuation in
          part U.S. Patent Application, Serial Number 07/531900 filed 1 June

<PAGE>   2
          1990, including the information contained in such application with
          respect to the Invention(s), any foreign patents corresponding
          thereto, and/or any divisions, continuations, or reissue thereof, but
          excluding continuation-in-parts to the extent that the claims are not
          adequately supported in the cases as originally filed above.

     2.2  "Technology" means existing technical data and information provided
          to LICENSEE and pertaining to the Invention(s) whether or not it is of
          a confidential nature. Exhibit A lists Technology.

     2.3  "Licensed Product(s)" means any product or part thereof in the
          Licensed Field-of-Use, the manufacture, use, or sale of which:
          (a)  is covered by a valid claim of an issued, unexpired Licensed
               Patent(s) directed to the Invention(s). (Claim of an issued,
               unexpired Licensed Patent(s) shall be presumed to be valid unless
               and until it has been held to be invalid by a final judgment of a
               court of competent jurisdiction from which no appeal can be or is
               taken); or
          (b) is covered by any claim being prosecuted in a pending application
               directed to the Invention(s).

     2.4  "Net Sales" means the gross revenue of the Licensed Product(s) in the
          form in which it is sold, leased, or used, whether or not assembled
          (but excluding therefrom, optional software or hardware that is not
          required to make the Licensed Product perform its basic function and
          is priced separately to customers of LICENSEE), less the following
          items but only insofar as they actually pertain to the disposition of
          such Licensed Product(s) by LICENSEE and are included in such gross
          income, and (except Item(d)) are separately billed:
          (a)  import, export, excise, and sales taxes, plus custom duties;
          (b)  costs of insurance, packing, and transportation from the place
               of manufacture to the customer's premises or point of
               installation;
          (c)  costs of installation at the place of use; and
          (d)  credit for returns, allowances, or trades.

     2.5  "Licensed Field-of-Use" means biological instrumentation.

     2.6  "Licensed Territory" means worldwide.

                               Page 2 of 14 Pages                       OTL #5
                                                                        6/19/90

<PAGE>   3
THE SYMBOL "[*]" IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

     2.7  "Exclusive" means REGENTS shall not grant further licenses in the
          Licensed Territory in the Licensed Field-of-Use, subject to Article 4
          (if applicable).

3.   GRANT

     3.1  REGENTS hereby grant and LICENSEE hereby accepts a license in the
          Licensed Field-of-Use to make, have made, use, lease and sell
          Licensed Product(s) in the Licensed Territory.

     3.2  Said license shall be Exclusive in the Licensed Field-of-Use for a
          term commencing as of the effective date of this Agreement and ending
          on 30 May 2000.

     3.3  At the end of the exclusive period, the license granted hereunder
          shall be nonexclusive until expiration of the last to expire of
          Licensed Patent(s).

     3.4  REGENTS expressly reserve the right to use the Invention(s) and
          associated technology for educational and research purposes.

4.   GOVERNMENT RIGHTS

     Unless LICENSEE is notified to the contrary, this Agreement is subject to
     Public Law 96-517 as amended, and LICENSEE agrees to take all action
     necessary on its part as a licensee to enable REGENTS to satisfy its
     obligations thereunder, relating to the Invention(s) and Licensed
     Patent(s) covered by this Agreement.

5.   ROYALTIES

     5.1  In exchange for the license granted pursuant to this agreement,
          LICENSEE agrees to pay to REGENTS:
          (a)  a noncreditable, nonrefundable license issue royalty of [*]
               dollars ($[*]) upon signing of the Agreement;
          (b)  [*]) shares of Molecular Dynamic common stock upon
               issuance of the first of U.S. Licensed Patent(s) filed by
               REGENTS, which patent(s) shall, in all material respects,
               contain the claims as set forth in the applications; provided,
               however, that if such patent(s) do not issue within two years
               after date of first appeal the LICENSEE shall have no obligation
               to issue such shares.

                               Page 3 of 14 Pages                       OTL #5
                                                                        6/19/90
<PAGE>   4
THE SYMBOL "[*]" IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

     5.2  Beginning 1 June 1992 and each 1 June thereafter, for a total of five
          (5) years, LICENSEE also shall pay to REGENTS a minimum annual royalty
          of [*] dollars ($[*]). Said minimum royalty payments are
          nonrefundable but they are creditable against earned royalties to the
          extent provided in Paragraph 5.5. In the event cumulative royalty
          tools are restarted pursuant to Paragraph 5.3(d), the minimum annual
          royalty requirements, as stated, shall also restart.

     5.3  In addition, LICENSEE shall pay REGENTS earned royalties as follows.

          (a)  For the first [*] dollars ($[*]) in cumulative sales, an amount
               equal to [*] percent ([*]%) of Net Sales of the licensed
               product(s) used, leased or sold by or for LICENSEE.

          (b)  For the next [*] dollars ($[*]) in cumulative sales, an amount
               equal to [*] percent ([*]%) of the net sales of the licensed
               product(s) used, leased, or sold by or for LICENSEE.

          (c)  For cumulative sales greater than [*] dollars ($[*]), an amount
               equal to [*] percent ([*]%) of the net sales of the licensed
               product(s) used, leased, or sold by or for LICENSEE.
          (d)  Cumulative sales totals and corresponding percent royalties due
               shall restart at zero with the first sale of each substantially
               new derivative product developed using the licensed technology.

     5.4  If LICENSEE believes patent rights have become materially diluted by
          the time of issue, such that the exclusive rights to practice the
          Invention, as contemplated by this Agreement, are not enjoyed by
          LICENSEE, REGENTS agree to an appropriate reduction in the earned
          royalties specified in Paragraph 5.3 above. The reduced earned royalty
          rate schedule shall be determined by good faith negotiations between
          LICENSEE and REGENTS, considering factors listed in Exhibit B hereto.
          If the parties cannot agree, the matter shall be presented to a single
          third party arbitrator, selected pursuant to procedure of Paragraph
          14.5, who shall be requested to determine a fair reduced earned
          royalty schedule, considering arguments of both parties. The parties
          agree to abide by such determination of the arbitrator.

     5.5  Creditable payments under this Agreement shall be an offset to
          LICENSEE against up to fifty percent (50%) of each earned royalty
          payment which LICENSEE would be required to pay pursuant to Paragraph
          5.3 until the entire credit is exhausted.

                               Page 4 of 14 Pages                       OTL #5
                                                                        6/19/90
<PAGE>   5
     5.6  If this Agreement is not terminated in accordance with other
          provisions hereof, LICENSEE's obligation to pay royalties hereunder
          shall continue until the latter of:

          (a)  four years from the date of first sale to a retail customer, if
               no Licensed Patent(s) issues; or

          (b)  for so long as LICENSEE, by its activities would, but for the
               license granted herein, infringe a valid claim of an unexpired
               Licensed Patent(s) of REGENTS covering said activity.

     5.7  The royalty on sales in currencies other than U.S. Dollars shall be
          calculated using the exchange rate calculated by averaging the rate
          stated in the Wall Street Journal on each Friday of each month.
          Royalty and payments to REGENTS shall be in U.S. Dollars and shall be
          net of all non-U.S. taxes.

6.   PATENT PROSECUTION

     6.1  REGENTS agree to provide LICENSEE copies of all office actions and
          other patent office and LICENSEE communications pertaining to Licensed
          Patent.

     6.2  REGENTS agree to seek, at the expense of LICENSEE, patent coverage for
          U.S. Licensed Patents in foreign countries selected by LICENSEE, upon
          sufficient notice to REGENTS in advance of foreign patenting bar
          dates.

          6.2.1  Such foreign patent applications and resulting patents shall
                 be included in LICENSED PATENTS.

          6.2.2  REGENTS may file title, for its own account and purposes,
                 corresponding foreign patent applications in countries not
                 selected by LICENSEE.

     6.3  Within thirty (30) days after receipt of a statement from REGENTS,
          LICENSEE shall reimburse REGENTS for all costs incurred by REGENTS in
          connection with the filing and prosecution of all patent applications
          requested by the LICENSEE and maintenance fees associated with the
          Licensed Patent(s).

     6.4  REGENTS, as represented by the Office of Technology Licensing at the
          University of California, Berkeley, agree to disclose to the LICENSEE,
          to the best of its knowledge, any knowledge of other patents, issued
          or applied for, that may impact the prosecution of Licensed Patent(s).

                               Page 5 of 14 Pages                       OTL #5
                                                                        6/19/90
<PAGE>   6
7.   RECORDS, REPORTS, AND PAYMENTS

          7.1       RECORDS--LICENSEE shall keep full, true and accurate books
                    of account containing all particulars that may be necessary
                    for the purpose of showing the amount of royalties payable
                    to REGENTS. Said books of account shall be kept at
                    LICENSEE's principal place of business or the principal
                    place of business of the appropriate Division of LICENSEE to
                    which this Agreement relates. Said books and the supporting
                    data shall be open at all reasonable times, for five (5)
                    years following the end of the calendar year to which they
                    pertain, to the inspection and audit by an independent
                    certified public accountant retained by the REGENTS for the
                    purpose of verifying LICENSEE's royalty statement or
                    compliance in other respects with this Agreement. Such
                    examination of LICENSEE's records shall be at the expense of
                    REGENTS, except in the event that the results of the audit
                    reveal a discrepancy in LICENSEE's favor of ten percent
                    (10%) or more, then the audit fees shall be paid by
                    LICENSEE.

          7.2       REPORTS--LICENSEE, within sixty (60) days after March 31,
                    June 30, September 30 and December 31, of each year, shall
                    deliver to REGENTS true and accurate reports, giving such
                    particulars of the business conducted by LICENSEE during the
                    preceding three-month period under this Agreement as shall
                    be pertinent to a royalty accounting hereunder. These shall
                    include at least the following.

                    (a)  The number of Licensed Products manufactured and the
                         number sold.

                    (b)  Gross revenue for Licensed Products sold.

                    (c)  Net Sales pursuant to paragraph 2.4.

                    (d)  Total royalties due REGENTS.

                    (e)  Names and addresses of sublicenses along with copy of
                         each new agreement entered into during the reporting
                         quarter.

                    (f)  Annually, a copy of LICENSEE's certified financial
                         statement for the preceding twelve (12) months
                         including, as a minimum, a balance sheet and an
                         operating statement.

          7.3       PAYMENTS--With each quarterly report as required under
                    paragraph 7.2, LICENSEE shall pay to REGENTS the royalties
                    due and payable under this Agreement pursuant to Article 5.
                    Payment shall be by check, payable to "The Regents

                               Page 6 of 14 Pages                       OTL #5
                                                                        6/19/90
<PAGE>   7
          of the University of California." Requires reports and payments shall
          be forwarded to REGENTS at address shown in Article 20.

8.  NEGATION OF WARRANTIES

     8.1  Nothing in this Agreement is or shall be construed as:

          (a)  a warranty or representation by REGENTS as to the validity or
               scope of any Licensed Patent(s);

          (b)  a warranty or representation that anything made, used, sold, or
               otherwise disposed of under any license granted in this Agreement
               is or will be free from infringement of patents, copyrights, and
               other rights of third parties;

          (c)  an obligation to bring or prosecute actions or suits against
               third parties for infringement, except to the extent and in the
               circumstances described in Article 11; or

          (d)  granting by implication, estoppel, or otherwise any licenses
               under patents of REGENTS or other persons other than Licensed
               Patent(s), regardless of whether such patents are dominant or
               subordinate to any Licensed Patent(s).

     8.2  Except as expressly set forth in this Agreement, REGENTS MAKE NO
          REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS
          OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF
          MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE
          OF THE LICENSED PRODUCT(S) WILL NOT INFRINGE ANY PATENT, COPYRIGHT,
          TRADEMARK, OR OTHER RIGHTS.

9.  INDEMNIFICATION

     9.1  LICENSEE agrees, and agrees to require its sublicensees, to indemnify,
          hold harmless, and defend REGENTS and its officers, employees,
          students, agents, sponsor(s) of the research that led to the
          Invention(s), and Inventor(s), against any and all liability, claims,
          suits, losses, damages, costs, fees and expenses for death, illness,
          personal injury, property damage, and improper business practices
          arising out of the manufacture, use, sale, lease, or other disposition
          of Invention(s), Licensed Patent(s), or Licensed Product(s) by
          LICENSEE and its sublicensees, and customers.

                               Page 7 of 14 Pages                       OTL #5
                                                                        6/19/90
<PAGE>   8
     9.2  The LICENSEE, at its sole costs and expense, shall insure its
          activities in connection with the work under this Agreement and
          obtain, keep in force and maintain insurance as follows:

          Comprehensive or Commercial Form General Liability Insurance
          (contractual liability and products liability included) with limits as
          follows:

          (a) each Occurrence                                    $1,000,000
          (b) products/Completed Operations Aggregate            $2,000,000
          (c) personal and Advertising Injury                    $1,000,000
          (d) general Aggregate (commercial form only)           $2,000,000

          It should be expressly understood, however, that the coverages and
          limits referred to under the above shall not in any way limit the
          liability of LICENSEE. LICENSEE shall furnish REGENTS with
          certificates of insurance evidencing compliance with all requirements.

     9.3  Insurance coverage as required under paragraph 9.2 above, shall:

          (a) provide for thirty (30) day advance written notice to REGENTS of
              cancellation or of any modification;

          (b) indicate that "The Regents of the University of California" and
              its officers, employees, students, agents, have been endorsed as
              additional insureds; and

          (c) include a provision that the coverages will be primary and will
              not participate with, nor will be excess over, any valid and
              collectible insurance or program of self-insurance carried or
              maintained by REGENTS.

10.  MARKING

     Prior to the issuance of patents on the Invention(s), LICENSEE agrees to
     mark Licensed Products (or their containers or labels) made, sold, or
     otherwise disposed of by it under the license granted in this Agreement
     with the words "Patent Pending," and following the issuance of one or more
     patents, with the numbers of the Licensed Patent(s). All Licensed Products
     shipped to, manufactured, or sold, in other countries shall be marked in
     such manner as to conform with the patent laws and practice of such
     countries.

11. PROMOTIONAL ADVERTISING

     LICENSEE agrees not to identify REGENTS in any promotional advertising or
     other promotional materials to be disseminated to the public or to use the
     name of any REGENTS faculty member,

                               Page 8 of 14 Pages                       OTL #5
                                                                        6/19/90
<PAGE>   9
THE SYMBOL "[*]" IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

     employee, or student or any trademark, service mark, trade name, or
     symbol, or abbreviation of REGENTS without REGENTS' prior written consent.

12. PATENT INFRINGEMENT

    12.1      If LICENSEE  shall learn of the substantial infringement of any
              Licensed Patent(s) under this Agreement, the LICENSEE shall
              promptly inform REGENTS with reasonable evidence of such
              infringement. Both parties to this Agreement agree that during
              the period and in a jurisdiction where the LICENSEE has exclusive
              rights under this Agreement, neither will notify a third party of
              the infringement without first obtaining consent of the other
              Party, which consent shall not be unreasonably denied. Both
              parties shall use their best efforts, in cooperation with each
              other, to terminate such infringement without litigation.

    12.2      The LICENSEE may request that REGENTS take legal action against
              the infringement. Such request shall be made in writing and shall
              include reasonable evidence of such infringement and damages to
              the LICENSEE. If the infringing activity has not been abated
              within ninety (90) days following the effective date of such
              request, REGENTS shall have the right to:

              (a) commence suit on their own account; or

              (b) refuse to participate in such suit, and REGENTS shall give
                  notice of their election in writing to LICENSEE by the end of
                  the one-hundredth (100th) day after receiving notice of such
                  request from the LICENSEE. The LICENSEE may thereafter bring
                  suit for patent infringement if, and only if, REGENTS elects
                  not to commence suit (other than as nominal party plaintiff),
                  and if the infringement occurred during the period and in a
                  jurisdiction where LICENSEE had exclusive rights under this
                  Agreement. However, in the event the LICENSEE elects to bring
                  suit in accordance with this paragraph, REGENTS may
                  thereafter join such suit at its own expense.
    12.3     [*]

                               Page 9 of 14 Pages                       OTL #5
                                                                        6/19/90
<PAGE>   10
    12.4      Each party agrees to cooperate with the other in litigation
              proceedings instituted hereunder but at the expense of the party
              on account of whom suit is brought. Such litigation shall be
              controlled by the party bringing the suit, except that REGENTS
              may be represented by counsel of its choice in any suit brought
              by LICENSEE.

13. DILUTION OF EQUITY

    During the term of this Agreement, and in the case of late stock offerings
    by LICENSEE to other parties which would result in a dilution or lowering
    of the percentage of REGENTS' equity in LICENSEE, LICENSEE shall offer to
    REGENTS, in writing, an additional number of shares, identical to the
    shares being sold, sufficient to maintain or restore its prior equity to
    the same percentage of ownership, said offer to be at the same price per
    share, as is offered to other party(ies) or to the public at that same
    time. REGENTS shall have thirty (30) days from receipt of the offer to
    accept said offer, or any part of it.

14. DUE DILIGENCE/PERFORMANCE MILESTONES

    14.1      LICENSEE shall diligently proceed with the development,
              manufacture, sale, or lease of Licensed Product(s) and shall
              earnestly and diligently endeavor to market the same within a
              reasonable time after execution of this Agreement and in
              quantities sufficient to meet market demands therefor.

    14.2      LICENSEE shall be entitled to exercise prudent and reasonable
              business judgement in meeting its due diligence obligations
              hereunder.

    14.3      LICENSEE shall endeavor to obtain all necessary governmental
              approvals for the manufacture, use, sale, or lease of Licensed
              Product(s).

    14.4      If the LICENSEE is unable to perform any of the following:

              (a) conduct an initial public offering before 1 June 1997; or

              (b) offer first Licensed Product(s) for sale by 1 January 1994,
                  then REGENTS shall have the right and option either to
                  terminate this Agreement or to reduce the LICENSEE's
                  exclusive license to a nonexclusive license. This right, if
                  exercised by REGENTS, supersedes the rights granted in
                  Article 3.

    14.5      Any controversy or claim arising out of or relating to the
              diligence provisions of this Agreement shall be settled by
              arbitration in accordance with the Licensing

                               Page 10 of 14 Pages                      OTL #5
                                                                        6/19/90
<PAGE>   11

              Agreement Arbitration Rules of the American Arbitration
              Association. Upon request of either party arbitration will be by:

              (a)  a third party arbitrator mutually agreed upon in writing by
                   LICENSEE and REGENTS within thirty (30) days of such
                   arbitration request; or

              (b)  a member of the American Arbitration Association.

              Judgement upon the award rendered by the Arbitrator may be
              entered in any court having jurisdiction thereof. The parties
              shall be entitled to discovery in like manner as if arbitration
              were a civil suit in the California Superior Court. Any
              arbitration shall be held in Berkeley, California, unless the
              parties hereto mutually agree writing to another place.

    14.6      REGENTS shall give LICENSEE sixty (60) days advance notice of any
              deficiency in due diligence. The LICENSEE shall cure said
              deficiency within said sixty (60) day period or request
              arbitration. If REGENTS have not received a written request for
              arbitration or satisfactory tangible evidence that the deficiency
              has been cured by the end of the sixty (60) day period, then
              REGENTS may, at its option, either terminate this Agreement or
              reduce the LICENSEE's exclusive license to a nonexclusive license
              by giving written notice to the LICENSEE.

    14.7      If REGENTS exercise its option to reduce the LICENSEE's exclusive
              license to a nonexclusive license for lack of diligence and,
              thereafter, REGENTS grant to a third party under another
              agreement a nonexclusive license to manufacture, use, sell or
              lease Licensed Product(s) at royalty rates more favorable than
              those contained herein, than the LICENSEE shall have the option
              for a period of one year after notice from REGENTS of such rates
              to substitute all royalty rates of the other agreement for all
              corresponding royalty rates of this Agreement provided the
              LICENSEE becomes obligated to the same terms and conditions of
              the other license.

15.  EXPORT CONTROLS

     LICENSEE understands that REGENTS are subject to United States Laws and
     regulations (including the Arms Export Control Act, as amended, and the
     Export Administration Act of 1979), controlling the export of technical
     data, computer software, laboratory prototypes and other commodities, and
     REGENTS' obligations under this Agreement are contingent on compliance with
     such laws and regulations. The transfer of certain technical data and
     commodities may require a license from the cognizant agency of the United
     States

                               Page 11 of 14 Pages                      OTL #5
                                                                        6/19/90
<PAGE>   12
     Government and/or written assurances by LICENSEE that LICENSEE shall not
     export such technical data and/or commodities to certain foreign countries
     without prior approval of such agency. REGENTS neither represents that a
     license shall not be required nor that, if required, it shall be issued.

16.  PREFERENCE FOR UNITED STATES INDUSTRY

     Because this Agreement grants the exclusive right to use or sell the
     Invention in the United States, LICENSEE agrees that, to the extent
     commercially feasible, any products embodying this Invention or produced
     through the use thereof for sale in the United States will be manufactured
     substantially in the United States.

17.  FOREIGN GOVERNMENTAL APPROVAL OR REGISTRATION

     If this Agreement or any associated transaction is required by the law of
     any nation to be either approved or registered with any governmental
     agency, LICENSEE shall assume all legal obligations to do so.

18.  TERMINATION

     18.1 LICENSEE may terminate this Agreement by giving REGENTS notice in
          writing at least thirty (30) days in advance of the effective date of
          termination selected by LICENSEE.

     18.2 REGENTS may terminate this Agreement if LICENSEE:

          (a)  is in default in payment of royalties or providing of reports; or

          (b)  is in breach of any provision hereof; or

          (c)  provides any materially false report; and LICENSEE fails to
               remedy any such default, breach, or false report within thirty
               (30) days after written notice thereof by REGENTS. (Pursuant to
               Paragraph 12.6, sixty (60) days notice shall be given for breach
               of Article 12.)

     18.3 Surviving any termination are:

          (a)  LICENSEE's obligation to pay royalties accrued or accruable;

          (b)  any cause of action or claim of LICENSEE or REGENTS, accrued or
               to accrue, because of any breach or default by the other party;

          (c)  the provisions of Articles 6, 7, and 8; and

          (d)  LICENSEES' right to sell inventory and to fill accepted orders.

                               Page 12 of 14 Pages                      OTL #5
                                                                        6/19/90
<PAGE>   13
19.  ASSIGNMENT

      This Agreement is binding upon and shall inure to the benefit of REGENTS,
      its successor and assigns, but shall be personal to the LICENSEE and
      assignable by the LICENSEE only with the written consent of REGENTS, which
      consent shall not be reasonably withheld. In the event where substantially
      all the assets of LICENSEE are acquired, all rights granted under this
      License shall automatically be transferred to the acquiree.

20.  NOTICES

      All notices under this Agreement shall be deemed to have been fully given
      when done in writing and deposited in the United States mail, registered
      or certified, and addressed as follows:

      To REGENTS:      Office of Technology Licensing
                       2150 Shattuck Avenue, Suite 510
                       Berkeley, CA 94704-1318
                       Attention: Director William A. Hoskins

      To LICENSEE:     Molecular Dynamics
                       880 East Arques Avenue
                       Sunnyvale, CA 94086
                       Attention: Jay Flatley

      Either party may change its address upon written notice to the other
      party.

21.  WAIVER

      21.1  The failure of either party to assert a right hereunder or to
            insist upon compliance with any term or condition of this Agreement
            shall not constitute a waiver of that right or excuse a similar
            subsequent failure to perform any such term or condition by the
            other party.

      21.2  None of the terms, covenants, and conditions of this Agreement can
            be waived except by the written consent of the party waiving
            compliance.

22.  SCOPE OF AGREEMENT

      This Agreement incorporates the entire agreement between the parties with
      respect to the subject matter hereof, and this Agreement may be altered
      or modified only by written amendment duly executed by the parties hereto.

                               Page 13 of 14 Pages                      OTL #5
                                                                        6/19/90
<PAGE>   14
23.  SEVERABILITY

     The provisions of this Agreement are several, and in the event that any
     provision of this Agreement shall be determined to be invalid or
     unenforceable under any controlling body of law, such invalidity or
     enforceability shall not in any way affect the validity or enforceability
     of the remaining provisions hereof.

24.  APPLICABLE LAW

     This Agreement shall be construed, interpreted, and applied in accordance
     with the laws of the State of California. Questions concerning the law and
     effect of the Licensed Patent shall be determined by the law of the country
     in which the patent was granted.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement in
duplicate originals by their duly authorized officers or representatives.

THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA                     MOLECULAR DYNAMICS

By: /s/ William A. Hoskins                   By: /s/ Jay Flatley
    ------------------------------------         ------------------------------
    William A. Hoskins
    Director, Office of Technology           Printed Name: JAY FLATLEY
    Licensing                                              --------------------

    Date: 1/16/91                                Title: C.O.O
          ------------------------------                -----------------------

                                                 Date: 1/14/91
                                                       ------------------------

                               Page 14 of 14 Pages                      OTL #5
                                                                        6/19/90
<PAGE>   15
                                                                       Exhibit A

                          LICENSE AGREEMENT - B90-001
                                    Between
                  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
                                      and
                               MOLECULAR DYNAMICS

                                   TECHNOLOGY

The following is an outline of the detailed description of LASER EXCITED
CONFOCAL FLUORESCENCE GEL SCANNER which follows.

1.   Optional System

     A.   Objective Lens

     B.   Beam Splitters, bandpass filters

     C.   Pinholes, spatial filters

     D.   Miscellaneous Optical Elements

2.   Detection, Image Acquisition and Scan Control

     A.   Photodetectors

     B.   Thermoelectric Cooled Phototube Housing

     C.   Photon Counting and Signal Processing Equipments

     D.   Analog-to-Digital Converters, computer interfacing boards

     E.   Computer Controlled XY Table

     F.   Frame Grabber Board

     G.   Microcomputer Systems

3.   Excitation Laser - Laser System

Figure 1  Apparatus (system block diagram)

Figure 2  Long pass beam splitter for fluorescein-like fluorophores

Figure 3  Long pass beam splitter for rhodamine-like fluorophores

Figure 4  Short pass beam splitter for rhodamine-like fluorophores

Figure 5  Bandpass beam splitter for fluorescein-like fluorophores

Figure 6  Bandpass beam splitter for rhodamine-like fluorophores
<PAGE>   16
                LASER EXCITED CONFOCAL FLUORESCENCE GEL SCANNER

The laser excited confocal fluorescence imaging system can be divided into
several different subsystems.

(1) Optical System:

A confocal optical arrangement is used to excite and collect fluorescence
emission. The purpose of the confocal arrangement is to reject out-of-focus
fluorescence or scattering by using spatial filtering. A 150 mm lens (Melles
Griot, plano-convex) is used to focus the laser beam in order to achieve
confocal excitation and probing of fluorescence. A long pass dichroic beam
splitter is used to reflect the laser beam through a 40X, N.A 0.6 long working
distance objective lens (Zeiss LD-EPIPLAIN) and onto the sample. Depending on
the fluorophores and the laser excitation wavelength, a long pass dichroic beam
splitter should be chosen which has steep spectral cut-on profile, long
transmission region, high reflectivity at the laser wavelength (>95%), and high
transmittance (>80%) for the fluorescence. For example, an Omega Optical 480
DRLP long pass beam splitter can be used for fluorophores such as fluorescein or
its derivatives that are excited by 488 nm. The fluorescence emission is
collected by the same objective and transmitted through the same long pass beam
splitter. Another beam splitter of short pass type can be used after the long
pass beam splitter to reflect fluorescence light toward photodetector while
letting the shorter wavelength scattered light through thus providing further
rejection of laser scatter. The transmission spectrum of the short pass beam
splitter should complement the long pass beam splitter. For example, for
rhodamine or fluorophores that are excited with 514.5 nm and have fluorescence
emission around 570 nm, an Omega Optical 520 DMLP can be used as the long pass
beam splitter and a 530 DMSP can be used as the short pass beamsplitter.

Due to the polarized nature of most argon ion laser emission, the polarization
of the laser beam is oriented to have minimum background scattering. In general,
this means the electric field vector of polarization should be aligned parallel
with the optical axis of the detector. In the configuration shown in Figure 1,
this means the long pass beam splitter should be s-plane polarized and the short
pass beam splitter should be p-plane polarized to optimally reject the
scatterings or reflections. To complete the confocal alignment and spatially
reject out-of-focus stray light, the fluorescence emission is passed through a
spatial filter which can be a pinhole of a diameter determined by the focused
beam waist in the sample and the magnification of the objective lens used. For
example, if the beam waist of the focused laser beam is 5 (micro)m and the
objective lens has 40X magnification then a pinhole approximately 400 (micro)m
in diameter should be chosen.

<PAGE>   17
A Fabry-Perot interference bandpass filter is used after the spatial filter to
further spectrally discriminate fluorescence from scattered light. An
interference filter with high number of Fabry-Perot cavities (less than 3) has a
sharp cut-on and cut-off passband shape and high attenuation outside the
passband. For multiple color detection, this is very important. With 488 nm
laser excitation, there is a strong and broad water Raman band around 570 nm and
if 514.5 nm excitation is used, the Raman scattering occurs around 620 nm. The
bandpass filter should be chosen according to the emission spectrum of the
fluorophore being used to have as wide a bandwidth as possible and to have as
high a transmittance (less than 85%) for the fluorescence while rejecting the
Raman and Rayleigh scattered light. For example, Omega Optical DF series
bandpass filters have a 6 cavity design and 10(-8) attenuation outside the
passband. The 530DF60 can be used with fluorescein excited at 488 nm and the
560DF70 can be used with rhodamine excited at 514.5 nm. For fluorophores whose
fluorescence emission is beyond 580 (with 488 nm excitation) or whose emission
is beyond 630 nm (with 514.5 nm excitation, a Schott cut-on series filter is
adequate and more economical.

To align the optical system, a gel of 0.25 to 1 mm thickness clad between two
glass plates of 1 to 1.5 mm thick is placed on the translation stage and
alignment is done with the aid of the reflections from different interfaces.
Due to the refractive index differences among the air, glasses, and gel, there
will be four different reflections on the spatial filter as one moves the
objective lens downward. The first reflection is from the air-cover glass
interface, the second one from the cover glass-gel interface, the third one
from the gel-glass plate interface, and the fourth one from the glass plate-air
interface. By knowing the thickness of the cover glass and the gel and with the
aid of a micrometer on the objective lens, one can easily position the focal
point or the probe volume in the center of the gel.

Sources:

A.   Objective lens:

          1.   Carl Zeiss, Inc.
               1 Zeiss Dr.
               Thornwood, NY 10594
               914-747-1800

          2.   Nikon Corp. Photo Group
               623 Stewart Ave.
               Garden City, NY 11530
               516-222-0200, FAX 516-222-2823

<PAGE>   18
B. Beam splitters, bandpass filters:

     1. Omega Optical, Inc.
        3 Grove St.
        Battleboro, VT 05301
        802-254-2690, FAX 802-257-0963

     2. CVI Laser Corp.
        200 Dorado Place, SE, PO Box 11308
        Albuquerque, NM 87192
        505-296-9541, FAX 505-298-9908

C. Pinholes, spatial filters

     1. Melles Griot Optics
        1770 Kettering St.
        Irvine, CA 92714
        714-261-5600, FAX 614-261-7589

     2. Rolyn Optics Co.
        706 Arrowgrand Circle
        Covina, CA 91722
        818-915-5707, FAX 818-915-1379

D. Miscellaneous optical elements:

     1. Melles Griot Optics
        1770 Kettering St.
        Irvine, CA 92714
        714-261-5600, FAX 614-261-7589

     2. Newport Corp.
        18235 Mt. Baldy Cir.
        Fountain Valley, CA 92708
        714-965-5458, FAX 714-963-2015

     3. Rolyn Optics Co.
        706 Arrowgrand Circle
        Covina, CA 91722
        818-915-5707, FAX 818-915-1379

(2) Detection, image acquisition and scan control:

A thermoelectric cooled (Products for Research, TE104RF) GaAs photomultiplier
tube with good quantum yield in the visible region (Hamamatsu 943 or RCA 31034A)
is usually a good choice for detector. Photon counting detection is used to
collect and process
<PAGE>   19
fluorescence signals. The photon counts can be processed in several different
ways. For example the digital counts can be processed by a timer/counter or by
a rate meter or by a frequency-to-voltage converter (Teledyne Philbrick 4736).
The output of the timer/counter can be sent to a computer via RS-232 serial
communication or by IEEE-488 bus or directly through computer I/O bus. The
output of a rate meter or a frequency-to-voltage converter is analog and can be
sampled by  a analog-to-digital converter. In applications where ultimate
detection sensitivity is not required, a small photomultiplier tube such as
Hamamatsu 928 operated at ambient temperature and with direct current detection
can be economical. In this kind of application, an analog-to-digital converter
is used for data acquisition.

A computer controlled motor driven XY translation stage with micrometer
resolution is used to translate the sample gel through the laser beam with scan
speed as high as 10 cm/sec. The complete system consists of a 2-axis motor
indexer or controller, motor drives, motors, and XY table. The system can be
controlled by a computer through RS-232c serial communication or IEEE-488
interfacing bus. The travel range of the XY table should be chosen to adequately
cover the area of the gel one intends to scan. Either a DC servo motor or
stepping motor can be used to drive the XY stages. A DC servo motor provides
closed loop control and smooth motion. For more accurate position control a DC
servo motor should be chosen. If open loop control is sufficient for the
application, stepping motors can be used. However, if smooth motion is required
at low speed, microstepping motors maybe more desirable than regular stepping
motors.

A microcomputer equipped with an analog-to-digital converter board or
counter/timer board is used to collect data. The computer should also be
equipped with either an RS-232c board or an IEEE-488 board to control the XY
translation stage. The graphic display design of a PC usually is not adequate
for image display and image processing. However, there are more advanced video
cards such as the super VGA (800 x 600 resolution, 256 colors) card or the
8514/A graphic card (1024 x 768 resolution, 256 colors) for IBM PS/2 can be
used for low cost image acquisition and display. A PC system with a video card
can be used to do basic image processing such as contrast enhancement, median
filtering, and pseudocoloring by software. If faster or more advanced image
processing is needed, a frame grabber board with 8-bit frame buffer, slow
scan synchronization input can be used. The present system makes one line scan
and displays acquired line image. The fluorescence images are psudo-color
encoded to represent different intensity levels and contrast stretched with
histogram equalization method to enhance the images. To quantitate the image
data, the image columns that enclose the bands are extracted and averaged.
<PAGE>   20
Sources:

A. Photodetectors:

     1. Hamamatsu Corp.
        360 Foothill Rd., PO Box 6910
        Bridgewater, NJ 08807
        201-231-0960, FAX 201-231-1539

     2. Burle Industries, Inc.
        1000 New Holland Ave.
        Lancaster, PA 17601
        717-295-6000

     3. Thorn EMI Electron Tubes, Ltd.
        23 Madison Rd.
        Fairfield, NJ 07006
        201-575-5586, FAX 201-575-8717

B. Thermoelectric cooled phototube housing:

     1. Products for Research, Inc.
        88 Holten St.
        Danvers, MA 01923
        508-774-3250, FAX 617-245-1628

     2. Hamamatsu Corp.
        360 Foothill Rd., PO Box 6910
        Bridgewater, NJ 08807
        201-231-0960, FAX 201-231-1539

C. Photon counting and signal processing equipments:

     1. Stanford Research Systems, Inc.
        1290 D. Reamwood Ave.
        Sunnyvale, CA 94089
        408-744-9049, FAX 408-706-891

     2. EG&G Princeton Applied Research Corp.
        7 Roszel Rd, PO Box 2565
        Princeton, NJ 08543
        609-452-2111, FAX 609-452-8510

     3. EG&G Ortec
        100 Midland Rd.
        Oak Ridge, TN 37831
        615-482-4411, FAX 615-483-0396
<PAGE>   21
          4.  Tennelec
              601 Oak Ridge Tpke.
              PO Box 2560
              Oak Ridge, TN 37831
              615-483-8405, FAX 615-483-5891

D.  Analog-to-digital converters, computer interfacing boards:

          1.  MetraByte Corp.
              440 Myles Standish Blvd.
              Taunton, MA 02780
              508-880-3000, FAX 508-880-0179

          2.  National Instruments
              12109 Technology Blvd.
              Austin, TX 78727
              512-794-0100

          3.  Data Translation, Inc.
              100 Locke Dr.
              Marlboro, MA 01752
              617-481-3700, FAX 617-481-8620

E.  Computer controlled XY Table:

          1.  Daedal, Inc.
              PO Box G
              Harrison City, PA 15636
              412-744-4451, FAX 412-744-7626

          2.  New England Affiliated Technologies
              620 Essex St.
              Lawrence, MA 01841
              508-685-4900, FAX 508-688-8027

          3.  Design Components Incorporated
              1 Kenwood Cir., Kenwood Industrial Park
              Franklin, MA 02038
              508-528-7300

          4.  Newport Corp.
              18235 Mt. Baldy Cir.
              Fountain Valley, CA 92708
              714-965-5458, FAX 714-963-2015

F.  Frame grabber board:

          1.  Imaging Technology, Inc.
              600 W. Cummings Park
              Woburn, MA 01801
              617-938-8444, FAX 617-938-1757

<PAGE>   22
          2.  Data Translation, Inc.
              100 Locke Dr.
              Marlboro, MA 01752
              617-481-3700, FAX 617-481-8620

G.  Microcomputer systems:

          1.  AST Research, Inc.
              16215 Alton Parkway
              Irvine, CA 92713
              714-727-4141

          2.  Arche Technologies, Inc.
              48881 Kato Rd.
              Fremont, CA 94539
              415-623-8100

          3.  Dell Computer Corp.
              9095 Arboretum Blvd.
              Austin, TX 78759
              800-426-5150

          4.  Acer America Crop.
              401 Charcot Ave.
              San Jose, CA 95131
              408-922-0333

          5.  Tatung Co. of America
              2850 El Presidio St.
              Long Beach, CA 90810
              213-637-2105

          6.  Wyse Technology
              3471 North First St.
              San Jose, CA 95134
              408-473-1200

(3)  Excitation Laser:

By the present configuration, fluorescence is excited by a Spectra-Physics 2020
argon ion laser operating at 514.5 or 488 nm with illuminating intensity from 1
- 20 mW at the gel. The laser system can be any argon ion laser system with
output power between 50 mW and 100 mW at either 514.5 nm or 488 nm depending on
the fluorophores. Such power can generally be provided by an air-cooled laser
with cost below $10,000
<PAGE>   23
Sources:

A. Laser system:

     1.   Omnichrome
          13620 Fifth St.
          Chino, CA 91710
          714-627-1594, FAX 714-591-8340

     2.   Spectra-Physics Laser Products Division
          1250 W. Middlefield Rd.
          Mountain View, CA 94039
          415-961-2550, FAX 415-969-4084

     3.   Laser Ionics, Inc.
          701 S. Kirkman Rd.
          Orlando, FL 32811
          407-298-1561, FAX 407-297-4167

     4.   Continental Laser Corp.
          3281 Scott Blvd.
          Santa Clara, CA 95052
          415-962-8402, FAX 415-962-0173

     5.   Lexel Lasers Inc.
          48503 Milmont Dr.
          Fremont, CA 94538
          415-770-0800, FAX 415-651-6598

     6.   Coherent Inc. Laser Products Div.
          3210 Porter Dr., PO Box 10321
          Palo Alto, CA 94303
          415-493-2111, FAX 415-493-1566

     7.   Ion Laser Technology, Inc.
          263 Jimmy Dolittle Rd.
          Salt Lake City, UT 84116
          801-537-1587, FAX 801-537-1590

REFERENCES

1. Wilson, T. and Sheppard, C. (1984) Theory and practice of scanning optical
microscopy, Academic Press, New York.

2. Ekstrom, M.P. (1984) Digital image processing techniques, Academic Press,
New York.

3. Peck, K; Stryer, L.; Glazer, A. N.; Mathies, R. A. (1989), Proc. Natl.
Acad. Sci. USA, 86, 4087-4091.
<PAGE>   24

                               [GRAPHIC OMITTED]

                              Figure 1.  Apparatus

<PAGE>   25

                               [GRAPHIC OMITTED]

      Figure 2.  Long pass beam splitter for fluorescein-like fluorophores
<PAGE>   26

                               [GRAPHIC OMITTED]

       Figure 3.  Long pass beam splitter for rhodamine-like fluorophores

<PAGE>   27

                               [GRAPHIC OMITTED]

       Figure 4.  Short pass beam splitter for rhodamine-like fluorophores

<PAGE>   28

                               [GRAPHIC OMITTED]

         Figure 5.  Band pass filter for fluorescein-like fluorophores
<PAGE>   29

                               [GRAPHIC OMITTED]

          Figure 6.  Band pass filter for rhodamine-like fluorophores
<PAGE>   30
                                                                       Exhibit B

                          LICENSE AGREEMENT - B90-001
                                    Between
                  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
                                      and
                               MOLECULAR DYNAMICS

                      FACTORS IN EARNED ROYALTY REDUCTION

-    Sales of Licensed Products(s) by Molecular Dynamics

-    Sales of Gel Scanners considered essentially equivalent to Licensed
     Product(s) by Molecular Dynamics and practicing one or more claims of
     Licensed Patents (Equivalent Licensed Product(s))

-    Market share of Molecular Dynamics versus that of vendors Equivalent
     Licensed Product(s), including present market shares and forecast market
     shares for remaining term of the license

-    Technical feature comparison of Licensed Product(s) versus Equivalent
     Licensed Product(s)

<PAGE>   31
                      AMENDMENT NO. 1 TO LICENSE AGREEMENT

     This Amendment No. 1 to that certain License Agreement (the "Agreement")
dated January 16, 1991 by and between The Regents of the University of
California (the "Regents") and Molecular Dynamics (the "Company") is made as of
the date last written below.

     WHEREAS, Section 13 of the Agreement provides that in the case of later
stock offerings by the Company to other parties which would result in a
dilution or lowering of the percentage of the Regents' equity in the Company,
the Company shall offer to the Regents an additional number of shares,
identical to the shares being sold, subject to other terms and conditions; and

     WHEREAS, the Company is currently contemplating the initial public
offering of its Common Stock (the "IPO") through its Delaware successor
corporation; and

     WHEREAS, both parties are willing to amend the Agreement to delete Section
13, as of the effective date of the Company's Registration Statement on Form
S-1 filed with respect to the IPO (the "Registration Statement") to facilitate
later stock offerings by the Company and enhance the value of such later stock
offerings, thereby benefitting the Regents.

     NOW THEREFORE, for good and adequate consideration, receipt of which is
hereby acknowledged, the parties agree as follows:

     1.  Section 13 of the Agreement is hereby deleted and shall be of no
further force or effect.

     2.  This Amendment No. 1 shall be effective as of the effective date of
the Registration Statement.

     3.  Except as modified herein, the Agreement shall remain in full force
and effect.

     4.  This Amendment No. 1 shall be construed, interpreted and applied in
accordance with the laws of the State of California.

<PAGE>   32
     IN WITNESS WHEREOF, the parties have executed this Amendment No. 1 as of
the dates indicated.

                                       THE REGENTS OF THE UNIVERSITY OF
                                       CALIFORNIA

                                       By: /s/ William A. Hoskins
                                           -------------------------------------
                                           William A. Hoskins
                                           Director, Office of
                                           Technology Licensing

                                       Date: Feb. 4, 1993
                                             -----------------------------------

                                       MOLECULAR DYNAMICS

                                       By: /s/ Jay T. Flatley
                                           -------------------------------------
                                           Jay T. Flatley
                                           President

                                       Date: 2/10/93
                                             -----------------------------------
<PAGE>   33
                                     WAIVER

     The undersigned hereby waives participation in the issuances of securities
of Molecular Dynamics, Inc. (the "Company") as provided in Section 13 of that
certain License Agreement (the "Agreement") dated January 16, 1991 by and
between The Regents of the University of California and the Company, whether
previously consummated or currently contemplated, including without limitation,
the initial public offering of the Common Stock of the Company (the "IPO"). In
the event the IPO is not consummated prior to June 30, 1993, this Waiver shall
be null and void with respect to the IPO.

                                       THE REGENTS OF THE UNIVERSITY OF
                                       CALIFORNIA

                                       By: /s/ William A. Hoskins
                                           -------------------------------------
                                           William A. Hoskins
                                           Director, Office of
                                           Technology Licensing

                                       Date: Feb. 4, 1993
                                             -----------------------------------
<PAGE>   34
UNIVERSITY OF CALIFORNIA AT BERKELEY
OFFICE OF TECHNOLOGY LICENSING                                [UC BERKELEY SEAL]
--------------------------------------------------------------------------------

                        AMENDMENT 2 TO LICENSE AGREEMENT

                                      FOR

               "LASER EXCITED CONFOCAL FLUORESCENCE GEL SCANNER"

                                                                Case No. B90-001
--------------------------------------------------------------------------------

THIS AGREEMENT is made on 15 day of May, 2000 ("Effective Date")

BETWEEN

(1)  THE REGENTS of the UNIVERSITY OF CALIFORNIA, a California corporation,
     whose legal address is 1111 Franklin Street, 12th Floor, Oakland, CA
     94607-5200, acting through its Office of Technology Licensing at the
     University of California, Berkeley, 2150 Shattuck Avenue, Suite 510,
     Berkeley, CA 94720-1620 ("Regents"); and

(2)  MOLECULAR DYNAMICS, INC., having a principal place of business as 928 East
     Arques Avenue, Sunnyvale, CA 94086 ("Licensee").

WHEREAS

A    The Regents and the Licensee are the parties to an Agreement dated 16
     January 1991 as amended by an Amendment Agreement dated 10 February 1993
     (together "the Agreement");

B    The parties wish to amend the terms of the Agreement as set out herein.

NOW THEREFORE, for good and adequate consideration and the payment by Licensee
to Regents of $1, receipt of which is hereby acknowledged, the parties agree as
follows:

1    The license which forms the subject matter of the Agreement shall be
     exclusive to Licensee, even to the exclusion of Regents, in the United
     Kingdom.

2    The period of exclusivity of the license shall be extended through the date
     of the last to expire patent under the Licensed Patents.

                                     Page 1

<PAGE>   35
The Licensee shall be permitted to grant sublicenses to third parties in the
Licensed Field-of-Use to make, have made, use, distribute and/or sell Licensed
Products.

To effect the agreement of the parties set out in Sections 1 through 3 above,
the Agreement shall be amended as set out in Section 5 through 7 below.

Paragraph 2.7 of the Agreement is hereby deleted and replaced with:

     2.7    "Exclusive" means:

     2.7.1  in that part of the Licensed Territory comprising the United Kingdom
            and its possessions, that Regents shall not itself make, have made,
            use, lease or sell Licensed Products in the Licensed Field-of-Use,
            nor shall Regents grant further licenses in the Licensed
            Field-of-Use, subject to Article 4 (if applicable); and

     2.7.2  in that part of the Licensed Territory other than the United Kingdom
            and its possessions, that Regents shall not grant further licenses
            in the Licensed Field-of-Use, subject to Article 4 (if applicable).

6    Paragraph 3.2 of the Agreement is hereby deleted and replaced with:

     3.2    Said license shall be Exclusive in the Licensed Field-of-Use for a
            term commencing as of the Effective Date of this Agreement and
            ending on the date of expiry of the last to expire of the Licensed
            Patents.

7    New paragraphs 3.5 through 3.7 shall be added as follows:

     3.5    Licensee shall have the right to sublicense to third parties in the
            Licensed Field-of-Use to make, have made, use, lease, distribute
            and/or sell Licensed Products provided that Licensee has current
            exclusive rights under this Agreement. Every such sublicense shall
            contain at least the following:

            (a)  A statement setting out the date upon which Licensee's
                 exclusive rights, privileges, and license hereunder shall
                 expire.

            (b)  A statement such that, to the extent applicable, the
                 obligations of this Agreement shall be binding upon the
                 sublicensee as if it were in place of Licensee, except that:

                 (i)   Earned royalty rate and minimum royalties may be at
                       higher rates than under this Agreement;

                 (ii)  Sublicensee(s) shall be precluded from granting further
                       sublicenses; and

                 (iii) Sublicensee(s) shall not be required to assume the
                       obligations due to Regents under paragraph 5.2 and
                       Sections 6, 14 and 17 of this Agreement. However, under
                       any sublicense, sublicensee shall at least be obligated
                       to Licensee under Sections 10 and 17.

                                     Page 2
<PAGE>   36
               (c)  The same provision for indemnification of Regents as has
                    been provided for in this Agreement.

          3.6  Licensee shall notify Regents of each sublicense granted
               hereunder and furnish to Regents a summary of the material terms
               of each such sublicense agreement.

          3.7  Licensee will collect and guarantee payment of any royalties due
               Regents from sublicensee(s); and deliver all reports due Regents
               and received from sublicensee(s).

          3.8  Upon termination of the Agreement for any reason, all sublicenses
               that are granted by Licensee pursuant to this Agreement shall
               remain in effect and shall be assigned to Regents except that
               Regents shall not be bound to perform any duties or obligation
               set forth in any sublicenses that extend beyond the duties and
               obligations of Regents set forth in this Agreement.

8    It is the intention of the parties that the amendments contained herein
     shall be effective as of the date of the Effective Date of this Amendment.

9    Except as modified herein, the Agreement shall remain in full force and
     effect.

10   This Amendment shall be construed, interpreted and applied in accordance
     with the laws of the State of California.

IN WITNESS WHEREOF, the parties have executed this Amendment on the dates
indicated.

THE REGENTS OF THE UNIVERSITY
OF CALIFORNIA

By: /s/ William A. Hoskins
    --------------------------------
      William A. Hoskins
      Director
      Office of Technology Licensing

Date: May 5, 2000
      ------------------------------

MOLECULAR DYNAMICS, INC.

By: /s/ M R Evans
    --------------------------------

Title: Director
       -----------------------------
Date: 11.5.2000
      ------------------------------

                                     Page 3<PAGE>   1
                                                                   EXHIBIT 10.11

THE SYMBOL "[*]" IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                               LICENSE AGREEMENT

     This Agreement is made and entered into between the President and Fellows
of Harvard College (hereinafter HARVARD) having offices at the Office for
Technology and Trademark Licensing, 124 Mt. Auburn Street, Suite 410 South,
Cambridge, Massachusetts, 02138 and Amersham Pharmacia Biotech Inc (hereinafter
LICENSEE), a corporation of Delaware having offices at 800 Centennial Avenue,
Piscataway, New Jersey 08855-1327. This Agreement consolidates, and supersedes
and replaces the License Agreements entered into by the parties on or about
October 1, 1986, September 1, 1988 and November 30, 1994. In the case of doubt
the terms of this Agreement shall govern.

     Whereas HARVARD is Owner by assignment from Stanley Tabor and Charles C.
Richardson of their entire right, title and interest in United States Patent
Application Serial No. 003,227 filed January 14, 1987 (HU Case no. 334), from
Stanley Tabor and Charles C. Richardson of their entire right, title and
interest in United States Patent Application Serial No. 218,103 filed July 12,
1988 (HU Case no. 483), from Stanley Tabor and Charles C. Richardson of their
entire right, title and interest in United States Patent Application Serial
324,437 filed October 17, 1994, (H.U. Case no 1077-94), the foreign patent
applications corresponding thereto, and in the inventions described and claimed
therein and listed in Appendix A; and

     Whereas HARVARD is committed to policy that ideas or creative works
produced at HARVARD should be used for the greatest possible public benefit; and

     Whereas HARVARD accordingly believes that every reasonable incentive
should be provided for the prompt introduction of such ideas into public use,
all in a manner consistent with the public interest; and

     Whereas LICENSEE is desirous of obtaining an exclusive world-wide license
in order to practice the above referenced invention covered by PATENT RIGHTS in
the United States and in certain foreign countries, and to manufacture, use and
sell in the commercial market the products made in accordance therewith; and

     Whereas HARVARD is desirous of granting such a license to LICENSEE in
accordance with the terms of this Agreement.

     Now therefore, in consideration of the foregoing premises, the parties
agree as follows:

                                       1

<PAGE>   2
                                   ARTICLE I

                                  DEFINITIONS

1.1  AFFILIATES shall mean any entity that directly or indirectly, through one
     or more intermediaries, controls, is controlled by or is under common
     control with a party to this Agreement, or where a party to this Agreement
     and another corporation are controlled by the same entity. For the purposes
     of this definition, control means the direct or indirect ownership of at
     least fifty percent (50%) (or such lesser percentage representing the
     maximum allowed to be owned by a foreign corporation in a particular
     jurisdiction) of (a) the outstanding voting securities of such entity or
     (b) the voting power of such entity. Unless otherwise, specified the term
     LICENSEE includes AFFILIATES.

1.2  LICENSED PRODUCTS shall mean products claimed in PATENT RIGHTS or products
     made in accordance with or by means of LICENSED PROCESSES. LICENSED
     PRODUCTS shall include kits incorporating LICENSED PRODUCTS.

1.3  LICENSED PROCESSES shall mean the processes claimed in PATENT RIGHTS.

1.4  NET SALES shall mean the amount billed or invoiced on sales of LICENSED
     PRODUCTS or LICENSED PROCESSES less:

     (a)  Customary trade, quantity or cash discounts and non-affiliated
          brokers' or agents' commissions actually allowed and taken;

     (b)  Amounts repaid or credited by reason of rejection or return; and/or

     (c)  To the extent separately stated on purchase orders, invoices or other
          documents of sale, taxes levied on and/or other governmental charges
          made as to the production, sale, transportation, delivery or use and
          paid by or on behalf of LICENSEE.

1.5  PATENT RIGHTS shall mean United States Patent Application Serial Numbers:
     003,227 filed January 14, 1987 (HU Case no. 334) 218,103 filed July 12,
     1988 (HU Case no. 483) 324,437 filed October 17, 1994 (HU Case no. 1077)
     the inventions described and claimed therein, and any divisions,
     continuations, continuations-in-part or re-issues thereof to the extent the
     claims are directed to subject matter specifically described in the
     foregoing patent applications and are dominated by the claims thereof; and
     any and all foreign patents and patent applications corresponding thereto,
     as well as such other patents or patent applications as are listed in
     Appendix A. Appendix A shall be updated from time to time by the parties to
     reflect the then pending applications and issued patents included in PATENT
     RIGHTS.

1.6  SUBLICENSE INCOME shall mean the total consideration, including but not
     limited to sublicense option or issue fees, maintenance fees, milestone
     payments and royalty

                                       2
<PAGE>   3
     payments received in cash or in kind, from the sublicensing of other
     companies to practice, teach or use PATENT RIGHTS in the course of
     manufacture, sale or distribution of the LICENSED PRODUCTS or LICENSED
     PROCESSES.

1.7  TECHNOLOGY shall mean any and all information, biological materials or
     PATENT RIGHTS supplied by HARVARD to LICENSEE.

1.8  USB shall mean USB Corporation, a corporation organized under the laws of
     Ohio and having its principal offices at 26111 Miles Road, Warrenville
     Heights, Ohio 44128. For the purposes of calculating royalties due to
     Harvard under Article III of this Agreement, sales by USB shall be treated
     as sales by an AFFILIATE.

1.9  The terms "Public Law 96-517" and "Public Law 98-620" include all
     amendments to those statutes.

1.10 The terms "sold" and "sell" include, without limitation, leases and other
     transfers and similar transactions.

                                   ARTICLE II

                                     GRANT

2.1  HARVARD hereby grants to LICENSEE and LICENSEE accepts, subject to the
terms and conditions hereof, a worldwide license under PATENT RIGHTS, with the
right to sublicense, to make and have made, to use and have used, to sell and
have sold, to import and have imported the LICENSED PRODUCTS, and to practice
the LICENSED PROCESSES, for the duration of the PATENT RIGHTS. In order to
provide LICENSEE with a period of exclusivity, HARVARD agrees it will not grant
licenses to others except as permitted in paragraphs 2.2(a), 2.2(b) and 2.3.
LICENSEE agrees during the period of exclusivity of this license in the United
States that any LICENSED PRODUCTS produced for sale in the United States will be
manufactured substantially in the United States unless a waiver is granted by
the Federal Agency under whose funding agreement the invention was made as
provided in Public Law 96-517, Section 204.

2.2  The granting and acceptance of this license is subject to the following
conditions:

     (a)  HARVARD's "Statement of Policy in Regard to Inventions, Patents and
          Copyrights" dated August 10, 1998, Public Law 96-517, Public Law
          98-620 and HARVARD's obligations under agreements with other sponsors
          of research. Any right granted in this Agreement greater than that
          permitted under Public Law 96-517 or Public Law 98-620 shall be
          subject to modification as may be required to conform to the
          provisions of that statute.

     (b)  HARVARD shall have the right to make and to use and to grant
          non-exclusive licenses to make and to use, for internal research
          purposes only and not for any

                                       3
<PAGE>   4
THE SYMBOL "[*]" IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
     commercial purpose, the subject matter described and claimed in PATENT
     RIGHTS.

(c)  LICENSEE shall, until the expiration of this Agreement, endeavor to keep
     LICENSED PRODUCTS reasonably available to the public.

(d)  HARVARD shall have the right to terminate or render this license
     non-exclusive at any time if, in HARVARD's reasonable judgment, LICENSEE:

     (i)  has not put the licensed subject matter into commercial use in the
          country or countries where licensed, directly or through a
          sublicense, and is not keeping the licensed subject matter reasonably
          available to the public, or

     (ii) is not demonstrably engaged in ongoing development, manufacturing,
          marketing or licensing program, as appropriate, directed toward this
          end.

     In making this determination HARVARD shall take into account the normal
     course of such programs conducted with sound and reasonable business
     practices and judgment and shall take into account the reports provided
     hereunder by LICENSEE.
(e)  LICENSEE has granted a sublicense under PATENT RIGHTS to [*]
     respectively, for worldwide rights to make and have made, to use and have
     used, to sell and have sold, to import and have imported the LICENSED
     PRODUCTS, and to practice the LICENSED PROCESSES, for the duration of the
     PATENT RIGHTS, in the area of manual sequencing products and processes. A
     copy of the sublicense agreement with [*] is attached to this Agreement as
     Appendix B.

(f)  All sublicenses granted by LICENSEE hereunder shall include a requirement
     that the sublicensee use its best efforts to bring the subject matter of
     the sublicense into commercial use as quickly as is reasonably possible and
     shall bind the sublicensee to meet LICENSEE's obligations to HARVARD under
     this Agreement. [*] Copies of all sublicense agreements shall be
     provided to HARVARD.

(g)  [*]

2.3  All rights reserved to the United States Government and others under Public
     Law 96-517 and 98-620 shall remain and shall in no way be affected by this
     Agreement

                                       4
<PAGE>   5
THE SYMBOL "[*]" IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
                                  ARTICLE III

                                   ROYALTIES
3.1  LICENSEE has paid to HARVARD the license fees stipulated in the License
     Agreements entered into by the parties on or about October 1, 1986,
     September 1, 1988 and November 30, 1994. LICENSEE has also agreed to make
     an additional payment of [*] LICENSEE will make this payment on or before
     March 1, 2000 [*]

3.2  LICENSEE shall pay to HARVARD during the term of this Agreement a royalty
     of [*] percent ([*]%) of NET SALES by LICENSEE and AFFILIATES, by USB
     under the sublicense referenced in Appendix B, or by future sublicensees.
     Payments on NET SALES under existing sublicenses to ABD and Roche shall be
     governed by paragraph 3.3.

     (a)  On sales between LICENSEE and its AFFILIATES or sublicensees for
          resale, the royalty shall be paid on the resale to a bona fide third
          party.

     (b)  Only one royalty shall be due and payable for a LICENSED PRODUCT and
          use thereof irrespective of the number of patents included within
          PATENT RIGHTS which are applicable to such LICENSED PRODUCT provided
          that said royalty shall be the highest applicable royalty.

     (c)  [*]

     (d)  If the license pursuant to the Agreement is converted to a
          non-exclusive one and if other non-exclusive licenses in the same
          field and territory are granted, the above royalties shall not exceed
          the royalty rate to be paid by other licensees in the same field and
          territory during the term of the non-exclusive license.

                                       5
<PAGE>   6
THE SYMBOL "[*]" IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

3.3  For existing sublicenses with [*] and [*], LICENSEE shall pay to HARVARD
     [*] percent ([*]%) of SUBLICENSE INCOME received by LICENSEE from
     sublicensees.

3.4  To the extent any sales of LICENSED PRODUCTS are made to the Government of
     the United States of America by LICENSEE or its AFFILIATES or sublicensees
     under a contract requiring a discounted or fixed price in which the
     Government invokes its royalty-free license, no royalty shall be payable
     hereunder to HARVARD for such sales.

3.5  In the event that the royalties paid to HARVARD are so significant a factor
     in the return realized by LICENSEE as to diminish LICENSEE's capability to
     respond to competitive pressures in the market, HARVARD agrees to consider
     a reasonable reduction in the royalty paid to HARVARD as to each LICENSED
     PRODUCT for the period during which such market condition exists. Factors
     determining the size of the reduction will include profit margin on
     LICENSED PRODUCTS and on analogous products, prices of competitive
     products, total prior sales by LICENSEE, and LICENSEE's expenditures on
     LICENSED PRODUCT development.

                                   ARTICLE IV

                                   REPORTING

4.1  LICENSEE shall provide written annual reports within sixty (60) days after
     June 30 of each calendar year which shall include but not be limited to:
     reports of progress on research and development, regulatory approvals,
     manufacturing, sublicensing, marketing and sales during the preceding
     twelve (12) months as well as plans for the coming year.

4.2  LICENSEE shall report to HARVARD the date of the first sale of LICENSED
     PRODUCTS (or results of LICENSED PROCESSES) in each country within thirty
     (30) days of occurrence.

4.3  (a)  LICENSEE agrees to submit to HARVARD within sixty (60) days after the
     calendar half years ending June 30 and December 31 reports setting forth
     for the preceding six (6) month period:

     (i)    the number of LICENSED PRODUCTS sold by LICENSEE, its AFFILIATES and
            sublicensees in each country;

     (ii)   total billings for such LICENSED PRODUCTS;

     (iii)  an accounting for all LICENSED PROCESSES used or sold;

     (iv)   deductions applicable to determine the NET SALES thereof;

     (v)    the amount of SUBLICENSE INCOME received by LICENSEE; and

                                       6
<PAGE>   7
     (vi)  the amount of royalty due thereon, or, if no royalties are due to
           HARVARD for any reporting period, the statement that no royalties are
           due.

     Such report shall be certified as correct by an officer of LICENSEE and
     shall include a detailed listing of all deductions from royalties.

     (b)   LICENSEE shall pay to HARVARD with each such Royalty Report the
           amount of royalty due with respect to such half year. Since multiple
           technologies are covered by the license granted hereunder, LICENSEE
           shall specify which PATENT RIGHTS or family of patents within PATENT
           RIGHTS are utilized for each LICENSED PRODUCT and LICENSED PROCESS
           included in the Royalty Report.

     (c)   All royalties due hereunder shall be payable in United States
           dollars. Conversion of foreign currency to U.S. dollars shall be
           made at the prevailing conversion rate existing in the United States
           shown in the New York Times on the last business day of the reporting
           period. All such reports shall be maintained in confidence by
           HARVARD, except as required by law, including Public Law 96-517 and
           98-620, and provided also that HARVARD may include in its usual
           reports total annual amounts of royalties paid. Late payment of
           royalties shall be subject to an interest charge of one and one half
           per cent (1 1/2%) per month of the outstanding sum.

                                   ARTICLE V

                                 RECORD KEEPING

5.1  LICENSEE shall keep, and shall require its AFFILIATES and sublicensees to
     keep accurate and correct records of LICENSED PRODUCTS or LICENSED
     PROCESSES made, used or sold under this Agreement, appropriate to determine
     the amount of royalties due hereunder to HARVARD. Such records shall be
     retained for at least three (3) years following a given reporting period.
     They shall be available during normal business hours for inspection at the
     expense of HARVARD by HARVARD's Internal Audit Department or by a Certified
     Public Accountant selected by HARVARD and approved by LICENSEE for the sole
     purpose of verifying reports and payments hereunder. Such accountant shall
     not disclose to HARVARD any information other than information relating to
     accuracy of reports and payments made under this Agreement. In the event
     that any such inspection shows an under reporting and underpayment in
     excess of five percent (5%) for any twelve (12) month period, then LICENSEE
     shall pay the cost of such examination as well as any additional sum that
     would have been payable to HARVARD had the LICENSEE reported correctly,
     plus interest.

                                   ARTICLE VI

               DOMESTIC AND FOREIGN PATENT FILING AND MAINTENANCE

6.1  LICENSEE shall reimburse HARVARD for all reasonable expenses HARVARD has
     incurred for the preparation, filing, prosecution and maintenance of PATENT
     RIGHTS

                                       7

<PAGE>   8
     and shall reimburse HARVARD for all such future expenses upon receipt of
     invoices from HARVARD. Late payment of these invoices shall be subject to
     interest charges of one and one-half percent (1 1/2%) per month. HARVARD
     shall, in its sole discretion, be responsible for the preparation, filing,
     prosecution and maintenance of any and all patent applications and patents
     included in PATENT RIGHTS. HARVARD shall consult with LICENSEE as to the
     preparation, filing, prosecution and maintenance of such patent
     applications and patents and shall furnish to LICENSEE copies of documents
     relevant to any such preparation, filing, prosecution or maintenance.

6.2  HARVARD and LICENSEE shall cooperate fully in the preparation, filing,
     prosecution and maintenance of PATENT RIGHTS and of all patents and patent
     applications licensed to LICENSEE hereunder, executing all papers and
     instruments or requiring members of HARVARD to execute such papers and
     instruments so as to enable HARVARD to apply for, to prosecute and to
     maintain patent applications and patents in HARVARD's name in designated
     territories, as listed in Appendix A. Designated territories may be added
     or deleted, and Appendix A accordingly modified, by written mutual consent
     of HARVARD and LICENSEE. Each party shall provide to the other prompt
     notice as to all matters which come to its attention and which may affect
     the preparation, filing, prosecution or maintenance of any such patent
     applications or patents.

6.3  LICENSEE may elect to surrender its PATENT RIGHTS in any country upon sixty
     (60) days written notice to HARVARD. Such notice shall not relieve LICENSEE
     from responsibility to reimburse HARVARD for patent-related expenses
     incurred prior to the expiration of the (60)-day notice period (or such
     longer period specified in LICENSEE's notice).

                                  ARTICLE VII

                                  INFRINGEMENT

7.1  With respect to any PATENT RIGHTS under which LICENSEE is exclusively
     licensed pursuant to this Agreement, LICENSEE shall have the right to
     prosecute in its own name and at its own expense any infringement of such
     patent, so long as such license is exclusive at the time of the
     commencement of such action. HARVARD agrees to notify LICENSEE promptly of
     each infringement of such patents of which HARVARD is or becomes aware.
     Before LICENSEE commences an action with respect to any infringement of
     such patents, LICENSEE shall give careful consideration to the views of
     HARVARD and to potential effects on the public interest in making its
     decision whether or not to sue.

7.2  If LICENSEE or its sublicensee elects to commence an action as described
     above and HARVARD is a legally indispensable party to such action, HARVARD
     shall have the right to assign to LICENSEE all of HARVARD's right, title
     and interest in each patent which is a part of the PATENT RIGHTS and is the
     subject of such action (subject to all HARVARD's obligations to the
     government and others having rights in such patent). In the event that
     HARVARD makes such an assignment, such assignment shall be irrevocable, and
     such action by LICENSEE on that patent or patents shall thereafter be

                                       8

<PAGE>   9
THE SYMBOL "[*]" IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

          brought or continued without HARVARD as a party, if HARVARD is no
          longer an indispensable party. Notwithstanding any such assignment to
          LICENSEE by HARVARD and regardless of whether HARVARD is or is not an
          indispensable party, HARVARD shall cooperate fully with LICENSEE in
          connection with any such action. In the event that any patent is
          assigned to LICENSEE by HARVARD, pursuant to this paragraph, such
          assignment shall require LICENSEE to continue to meet its obligations
          under this Agreement as if the assigned patent or patent application
          were still licensed to LICENSEE.

7.3       If LICENSEE elects to commence an action described above and HARVARD
          is a legally indispensable party to such action, HARVARD may join the
          action as a co-plaintiff. Upon doing so, HARVARD shall jointly
          control the action with LICENSEE.

7.4       LICENSEE shall reimburse HARVARD for any costs it incurs as part of
          an action brought by LICENSEE, irrespective of whether HARVARD shall
          become a co-plaintiff.
7.5       [*]

7.6       No settlement, consent judgment or other voluntary final disposition
          of the suit may be entered into without the consent of HARVARD, which
          consent shall not be unreasonably withheld.
7.7       [*]

7.8       In the event that LICENSEE and its sublicensee, if any, elect not to
          exercise their right to prosecute an infringement of the PATENT
          RIGHTS pursuant to the above paragraphs, HARVARD may do so at its own
          expense, controlling such action and retaining all recoveries
          therefrom.

7.9       Without limiting the generality of paragraph 7.8, HARVARD may, at its
          election and by notice to LICENSEE, establish a time limit of sixty
          (60) days for LICENSEE to decide whether to prosecute any
          infringement of which HARVARD is or becomes aware. If, by the end of
          such sixty (60)-day period, LICENSEE has not commenced such an
          action, HARVARD may prosecute such an infringement at its own expense,
          controlling such action and retaining all recoveries therefrom. With
          respect to any such infringement action prosecuted by HARVARD in good
          faith, LICENSEE shall pay over to Harvard any payments (whether or
          not designated as "royalties") made by the alleged infringer to
          LICENSEE under any existing or future sublicense authorizing LICENSED

                                       9
<PAGE>   10
      PRODUCTS, up to the amount of HARVARD'S unreimbursed litigation expenses
      (including, but not limited to, reasonable attorneys' fees).

7.10  If a declaratory judgment action alleging invalidity of any of the PATENT
      RIGHTS shall be brought against LICENSEE or HARVARD, then HARVARD, at its
      sole option, shall have the right to intervene and take over the sole
      defense of the action at its own expense.

                                  ARTICLE VIII

                            TERMINATION OF AGREEMENT

8.1   This Agreement, unless extended or terminated as provided herein, shall
      remain in effect until the last patent or patent application in PATENT
      RIGHTS has expired or been abandoned.

8.2   In the event LICENSEE fails to make payments due hereunder, HARVARD shall
      have the right to terminate this Agreement upon thirty (30) days written
      notice, unless LICENSEE makes such payments plus interest within the
      thirty (30) day notice period. If payments are not so made, HARVARD may
      immediately terminate this Agreement.

8.3   In the event that LICENSEE shall be in default in the performance of any
      obligation under this Agreement (other than as provided in 8.2 above which
      shall take precedence over any other default), and if the default has not
      been remedied within ninety (90) days after the date of notice in writing
      of such default, HARVARD may terminate this Agreement immediately by
      written notice. If upon receipt of such original notice in writing of such
      default LICENSEE believes that such default cannot be remedied within 90
      days, LICENSEE may so notify HARVARD in writing and propose a plan and
      deadline for remedy, which HARVARD may accept or reject in its sole
      discretion. If HARVARD accepts such plan and deadline, and if the default
      has not been remedied on or before such deadline, HARVARD may terminate
      this Agreement immediately by written notice. If HARVARD rejects such
      plan, and such default has not been remedied within ninety (90) days after
      the date of such original notice in writing of such default, HARVARD may
      terminate this Agreement immediately by written notice.

8.4   In the event that LICENSEE shall become insolvent, shall make an
      assignment for the benefit of creditors, or shall have a petition in
      bankruptcy filed for or against it, HARVARD shall have the right to
      terminate this entire Agreement immediately upon giving LICENSEE written
      notice of such termination.

8.5   Any sublicenses granted by LICENSEE under this Agreement shall provide for
      termination or assignment to HARVARD, at the option of HARVARD, of
      LICENSEE's interest therein upon termination of this Agreement.

8.6   Sections 5.1, 6.1, 7.7, 8.6, 9.2, 9.3, 9.4, 9.7 and 9.8 of this Agreement
      shall survive termination.

                                       10
<PAGE>   11
                                   ARTICLE IX

                                    GENERAL

9.1  HARVARD represents and warrants that Stanley Tabor and Charles Richardson
     have assigned to HARVARD their entire right, title, and interest in the
     patent applications or patents comprising the PATENT RIGHTS and that
     HARVARD has the authority to issue licenses under said PATENT RIGHTS.
     HARVARD does not warrant the validity of the PATENT RIGHTS licensed
     hereunder and makes no representations whatsoever with regard to the scope
     of the licensed PATENT RIGHTS or that such PATENT RIGHTS may be exploited
     by LICENSEE, an AFFILIATE, or sublicensee without infringing other patents.

9.2  HARVARD EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED OR EXPRESS WARRANTIES AND
     MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR
     ANY PARTICULAR PURPOSE OF THE PATENT RIGHTS OR TECHNOLOGY SUPPLIED BY
     HARVARD OR THE LICENSED PROCESSES OR LICENSED PRODUCTS CONTEMPLATED BY THIS
     AGREEMENT.

9.3 (a)   LICENSEE shall indemnify, defend and hold harmless HARVARD and its
          current or former directors, governing board members, trustees,
          officers, faculty, medical and professional staff, employees,
          students, and agents and their respective successors, heirs and
          assigns (the "Indemnitees"), against any liability, damage, loss or
          expenses (including reasonable attorneys' fees and expenses of
          litigation) incurred by or imposed upon the Indemnitees or any one of
          them in connection with any claims, suits, actions, demands or
          judgments arising out any theory of product liability (including, but
          not limited to, actions in the form of tort, warranty, or strict
          liability) concerning any product, process or service made, used or
          sold pursuant to any right or license granted under this Agreement,
          except to the extent directly attributable to the negligent, reckless
          misconduct or intentional misconduct of the Indemnitees.

     (b)  LICENSEE agrees, at its own expense, to provide attorneys reasonably
          acceptable to HARVARD to defend against any actions brought or filed
          against any party indemnified hereunder with respect to the subject of
          indemnity contained herein, whether or not such actions are rightfully
          brought.

     (c)  Beginning at the time as any such product, process or service is being
          commercially distributed or sold (other than for the purpose of
          obtaining regulatory approvals) by LICENSEE or by a sublicensee,
          AFFILIATE or agent of LICENSEE, LICENSEE shall, at its sole cost and
          expense, procure and maintain commercial general liability insurance
          in amounts not less than $2,000,000 per incident and $2,000,000
          annual, aggregate. During clinical trials of any such product, process
          or service, LICENSEE shall, at its sole cost and expense, procure and
          maintain commercial general liability insurance in such equal or
          lesser amount as HARVARD shall require. Such commercial general
          liability insurance shall provide (i) product liability coverage

                                       11

<PAGE>   12
          and (ii) broad form contractual liability coverage for LICENSEE's
          indemnification under this Agreement. Within thirty (30) days after
          execution of this Agreement, LICENSEE shall provide a commitment to
          maintain a self-insurance program which is reasonably satisfactory to
          HARVARD and the Risk Management Foundation of the Harvard Medical
          Institutions, Inc. The minimum amounts of insurance coverage required
          shall not be construed to create a limit of LICENSEE's liability with
          respect to its indemnification under this Agreement.

     (d)  LICENSEE shall provide HARVARD with written evidence of such insurance
          upon request of HARVARD. LICENSEE shall provide HARVARD with written
          notice at least thirty (30) days prior to the cancellation,
          non-renewal or material reduction in such insurance; if LICENSEE does
          not obtain replacement insurance providing comparable coverage within
          such thirty (30) day period, HARVARD shall have the right to terminate
          this Agreement effective at the end of such thirty (30) day period
          without notice or any additional waiting periods.

     (e)  LICENSEE shall maintain such commercial general liability insurance
          beyond the expiration or termination of this Agreement during (i) the
          period that any product, process, or service, relating to, or
          developed pursuant to, this Agreement is being commercially
          distributed or sold by LICENSEE or by a sublicensee, AFFILIATE or
          agent of LICENSEE and (ii) a reasonable period after the period
          referred to in (e) (i) above which in no event shall be less than five
          (5) years.

9.4  LICENSEE shall not use HARVARD's name or any adaptation of it or the name
     or names of any of HARVARD's investors in any advertising, promotional or
     sales literature without the prior written assent of HARVARD.

9.5  Without the prior written approval of HARVARD in each instance, neither
     this Agreement nor the rights granted hereunder shall be transferred or
     assigned in whole or in part by LICENSEE to any person whether voluntarily
     or involuntarily, by operation of law or otherwise, except that LICENSEE
     may transfer or assign this Agreement and the rights granted hereunder, in
     whole or in part, to an AFFILIATE or to a successor to substantially all of
     the business or particular product line for which this Agreement was
     entered into, and such succession shall include but not be limited to one
     by acquisition, merger, change of corporation name or change in make-up,
     organization, or identity. This Agreement shall be binding upon the
     respective AFFILIATES, successors, legal representatives and assignees of
     HARVARD and LICENSEE.

9.6  The interpretation and application of the provisions of this Agreement
     shall be governed by the laws of the Commonwealth of Massachusetts.

9.7  LICENSEE agrees to comply with all applicable laws and regulations. In
     particular, it is understood and acknowledged that the transfer of certain
     commodities and technical data is subject to United States laws and
     regulations controlling the export of such commodities and technical data,
     including all Export Administration Regulations of the United States
     Department of Commerce. These laws and regulations among other things,
     prohibit or require a license for the export of certain types of technical
     data to certain specified countries. LICENSEE hereby agrees and gives
     written assurance that it
                                       12
<PAGE>   13
     will comply with all United States laws and regulations controlling the
     export of commodities and technical data, that it will be solely
     responsible for any violation of such by LICENSEE or its AFFILIATES or
     sublicensees, and that it will defend and hold HARVARD harmless in the
     event of any legal action of any nature occasioned by such violation.

9.8  LICENSEE agrees to obtain all regulatory approvals required for the
     manufacture and sale of LICENSED PRODUCTS and LICENSED PROCESSES and to
     utilize appropriate patent marking on such LICENSED PRODUCTS. LICENSEE also
     agrees to register or record this Agreement as is required by law or
     regulation in any country where the license is in effect.

9.9  Written notices required to be given under this Agreement shall be
     addressed as follows:

     If to HARVARD:           Office for Technology and
                              Trademark Licensing
                              Harvard University
                              1350 Massachusetts Avenue, Holyoke 727
                              Cambridge, MA 02138

     With copies to:          Office for Technology Licensing
                              And Industry-Sponsored Research
                              Harvard Medical School
                              Building A, Room 414
                              25 Shattuck Street
                              Boston, MA 02115

     If to LICENSEE:          General Counsel
                              Amersham Pharmacia Biotech, Inc
                              800 Centennial Avenue,
                              Piscataway,
                              New Jersey 08855-1327

     or such other address as either party may request in writing.

9.11 Should a court of competent jurisdiction later consider any provision of
     this Agreement to be invalid, illegal, or unenforceable, it shall be
     considered severed from this Agreement. All other provisions, rights and
     obligations shall continue without regard to the severed provision,
     provided that the remaining provisions of this Agreement are in accordance
     with the intention of the parties.

9.12 In the event of any controversy or claim arising out of or relating to any
     provision of this Agreement or the breach thereof, the parties shall try to
     settle such conflicts amicably between themselves. Subject to the
     limitation stated in the final sentence of this section, any such conflict
     which the parties are unable to resolve shall be settled through
     arbitration conducted in accordance with the rules of the American
     Arbitration Association. The demand for arbitration shall be filed within a
     reasonable time after the controversy or claim has arisen, and in no event
     after the date upon which institution of

                                       13
<PAGE>   14
     legal proceedings based on such controversy or claim would be barred by the
     applicable statute of limitation. Such arbitration shall be held in
     Boston, Massachusetts. The award through arbitration shall be final and
     binding. Either party may enter any such award in a court having
     jurisdiction or may make application to such court for judicial acceptance
     of the award and an order of enforcement, as the case may be.
     Notwithstanding the foregoing, either party may, without recourse to
     arbitration, assert against the other party a third-party claim or
     cross-claim, in any action brought by a third party, to which the subject
     matter of this Agreement may be relevant.

9.13 This Agreement constitutes the entire understanding between the parties and
     neither party shall be obligated by any condition or representation other
     than those expressly stated herein or as may be subsequently agreed to by
     the parties hereto in writing.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized representatives.

The effective date of this Agreement is January 1, 1999.

PRESIDENT AND FELLOWS OF                AMERSHAM PHARMACIA BIOTECH INC.
HARVARD COLLEGE

By: /s/ Jeffrey Labovitz, Ph.D.         By: /s/ Ron Long
    ---------------------------             -----------------

Name and Title:                         Name and Title:

Jeffrey Labovitz, Ph.D.                 Ron Long
Director                                Director
Office of Technology Licensing &
Industry Sponsored Research

                                       14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]